Hsp90 alpha Antibody - #AF5368

>>买2送1 进行中>>
>>赠JD卡 进行中>>
(6)   (18)  
产品: Hsp90 alpha 抗体
货号: AF5368
描述: Rabbit polyclonal antibody to Hsp90 alpha
应用: WB IHC IF/ICC
文献验证: WB, IHC, IF/ICC
反应: Human, Mouse, Rat
预测: Pig, Bovine, Horse, Rabbit, Dog, Chicken
蛋白号: P07900
RRID: AB_2837853

浏览相似产品>>

   规格 价格 库存
 50ul RMB¥ 1250 现货
 100ul RMB¥ 2300 现货
 200ul RMB¥ 3000 现货

货期: 当天发货

联系销售
相关下载
MS Report
HPLC Report
MSDS
说明书
COA
实验方案
WB Handbook
IHC Protocol
IF/ICC Protocol

产品描述

来源:
Rabbit
应用:
WB 1:500-1:2000, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: 适用于变性蛋白样本的免疫印迹检测. IHC: 适用于组织样本的石蜡(IHC-p)或冰冻(IHC-f)切片样本的免疫组化/荧光检测. IF/ICC: 适用于细胞样本的荧光检测. ELISA(peptide): 适用于抗原肽的ELISA检测.

反应:
Human, Mouse, Rat
克隆:
Polyclonal
特异性:
Hsp90 alpha Antibody detects endogenous levels of total Hsp90 alpha.
RRID:
AB_2837853
引用格式: Affinity Biosciences Cat# AF5368, RRID:AB_2837853.
偶联:
Unconjugated.
纯化:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
保存:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
别名:

展开/折叠

EL52; epididymis luminal secretory protein 52; Heat shock 86 kDa; heat shock 90kD protein 1, alpha; Heat shock 90kD protein 1, alpha like 4; heat shock 90kD protein, alpha-like 4; Heat shock 90kDa protein 1 alpha; Heat shock protein 90kDa alpha (cytosolic) class A member 1; Heat shock protein HSP 90-alpha; HS90A_HUMAN; HSP 86; HSP86; Hsp89; HSP89A; Hsp90; HSP90A; HSP90AA1; HSP90ALPHA; HSP90N; HSPC1; HSPCA; HSPCAL1; HSPCAL4; HSPN; LAP 2; LAP2; lipopolysaccharide-associated protein 2; LPS-associated protein 2; Renal carcinoma antigen NY-REN-38;

抗原和靶标

免疫原:

A synthesized peptide derived from human Hsp90 alpha, corresponding to a region within C-terminal amino acids.

基因/基因ID:
HSP90AA1(3320)
描述:
FunctionMolecular chaperone. Has ATPase activity.Sequence similaritiesBelongs to the heat shock protein 90 family.Post-translational modificationsISGylated.

研究领域

· Cellular Processes > Cell growth and death > Necroptosis.   (View pathway)

· Environmental Information Processing > Signal transduction > PI3K-Akt signaling pathway.   (View pathway)

· Genetic Information Processing > Folding, sorting and degradation > Protein processing in endoplasmic reticulum.   (View pathway)

· Human Diseases > Cancers: Overview > Pathways in cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Prostate cancer.   (View pathway)

· Organismal Systems > Immune system > Antigen processing and presentation.   (View pathway)

· Organismal Systems > Immune system > NOD-like receptor signaling pathway.   (View pathway)

· Organismal Systems > Immune system > IL-17 signaling pathway.   (View pathway)

· Organismal Systems > Immune system > Th17 cell differentiation.   (View pathway)

· Organismal Systems > Endocrine system > Progesterone-mediated oocyte maturation.

· Organismal Systems > Endocrine system > Estrogen signaling pathway.   (View pathway)

文献引用

1). RETRACTED ARTICLE: Hsp90β promotes aggressive vasculogenic mimicry via epithelial–mesenchymal transition in hepatocellular carcinoma. Oncogene, 2018 (PubMed: 30087438) [IF=6.9]
2). Hsp90β promotes aggressive vasculogenic mimicry via epithelial-mesenchymal transition in hepatocellular carcinoma. ONCOGENE, 2023 (PubMed: 30087438) [IF=6.9]

Application: IHC    Species: human    Sample: HCC cells

Fig. 1| Hsp90βassociates with vasculogenic mimicry and poor prog-nosis in HCC. e Representative images of Hsp90β, Hsp90α, VE-cadherin,E-cadherin, Vimentin, MMP2, and MMP9 expression in VM/Hsp90βnegative and positive HCC tissue samples. All images are repre-sentative.

Application: WB    Species: human    Sample: PLC-PRF-5 cells

Fig. 3| Hsp90β interacts with Twist1 in HCC. a Immunopurification and mass spectrometry analysis of Hsp90β-(left) and Twist1-associated proteins (right). b Whole-cell lysates from PLC-PRF-5 cells were immunoprecipitated (IP) followed by immunoblotting (IB)with antibodies against the indicated proteins.
3). Sequential targeting biomimetic nano platform for enhanced mild photothermal therapy and chemotherapy of tumor. Computational and structural biotechnology journal, 2023 (PubMed: 37181660) [IF=4.4]

Application: WB    Species: Mouse    Sample: CAFs and 4T1cells

Fig. 4. Synergistic in vitro cancer inhibition effects of PTT and chemotherapy strategy mediated by mPDA/Cur@M/CM. (A) In vitro viability of CAFs treated with mPDA/Cur@M/CM at different curcumin concentrations with or without laser irradiation (808 nm, 0.4 W/cm2, 10 min) (A). Viability of CAFs cells received different treatment (B). In vitro viability of 4T1 cells treated with mPDA/Cur@M/CM containing different curcumin concentrations in the presence or absence of laser irradiation (808 nm, 0.4 W/cm2, 10 min) (C). Viability of 4T1 cells received different treatment (D), n = 4, ∗p 
4). HSP90 Inhibitor Ganetespib (STA-9090) Inhibits Tumor Growth in c-Myc-Dependent Esophageal Squamous Cell Carcinoma. OncoTargets and Therapy, 2020 (PubMed: 32308431) [IF=2.7]

Application: IF/ICC    Species: Human    Sample: Eca-109 cells

Figure 1 MYC was over-expressed and interacted with HSP90 in ESCC. (A and B) MYC’ nuclear expression in ESCC. Images from TMA immunostained for MYC. Scale bars represent 50 μm. (C) MYC expression against HSP90 expression status showing 50% of double-positive samples. (D) Western blotting examined the expression of MYC in ESCC tumor tissues and adjacent normal tissues (n=12). (E) Localization of HSP90 and MYC in Eca-109 cells by immunofluorescence. Scale bars represent 25 μm. (F) Interaction of endogenous HSP90 with MYC was detected by co-IP assays in Eca-109 cells. ***P < 0.001.

Application: WB    Species: Human    Sample: Eca-109 cells

Figure 1 MYC was over-expressed and interacted with HSP90 in ESCC. (A and B) MYC’ nuclear expression in ESCC. Images from TMA immunostained for MYC. Scale bars represent 50 μm. (C) MYC expression against HSP90 expression status showing 50% of double-positive samples. (D) Western blotting examined the expression of MYC in ESCC tumor tissues and adjacent normal tissues (n=12). (E) Localization of HSP90 and MYC in Eca-109 cells by immunofluorescence. Scale bars represent 25 μm. (F) Interaction of endogenous HSP90 with MYC was detected by co-IP assays in Eca-109 cells. ***P < 0.001.
5). Comparative proteomics identify HSP90A, STIP1 and TAGLN‑2 in serum extracellular vesicles as potential circulating biomarkers for human adenomyosis. Experimental and Therapeutic Medicine, 2022 (PubMed: 35495589) [IF=2.4]

Application: WB    Species: human    Sample: T‑AMEVs and B‑AMEVs

Figure 4. | HSP90A, STIP1 and TAGLN‑2 are expressed in B‑AMEVs and T‑AMEVs. (D and E) HSP90A, STIP1 and TAGLN‑2 were present in T‑AMEVs and B‑AMEVs from patients with adenomyosis,but not in those of patients in the control group.
6). Efficacy of Danlou tablet on myocardial ischemia/ reperfusion injury assessed by network pharmacology and experimental verification. Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 2024 (PubMed: 38213248) [IF=2.0]

限制条款

产品的规格、报价、验证数据请以官网为准，官网链接：www.affbiotech.com | www.affbiotech.cn（简体中文）| www.affbiotech.jp（日本語）

产品的数据信息为Affinity所有，未经授权不得收集Affinity官网数据或资料用于商业用途，对抄袭产品数据的行为我们将保留诉诸法律的权利。

产品相关数据会因产品批次、产品检测情况随时调整，如您已订购该产品，请以订购时随货说明书为准，否则请以官网内容为准，官网内容有改动时恕不另行通知。

Affinity保证所销售产品均经过严格质量检测。如您购买的商品在规定时间内出现问题需要售后时，请您在Affinity官方渠道提交售后申请。

产品仅供科学研究使用。不用于诊断和治疗。 

产品未经授权不得转售。

Affinity Biosciences将不会对在使用我们的产品时可能发生的专利侵权或其他侵权行为负责。Affinity Biosciences, Affinity Biosciences标志和所有其他商标所有权归Affinity Biosciences LTD.